Enzalutamide as monotherapy for advanced prostate cancer: why not?
CONCLUSION: It is mandatory to validate these early results on the use on Enzalutamide monotherapy for advanced prostate cancer, hormone-sensitive or castration resistant, metastatic or not, but in the meantime, we wonder, why not?
PMID: 27617558 [PubMed - as supplied by publisher]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
More News: Bile | Cancer | Cancer & Oncology | Clinical Trials | Hormones | Prostate Cancer | Study | Toxicology | Urology & Nephrology